Distinct time pattern of complement activation and cytotoxic T cell response in Guillain-Barré syndrome

Brain

Volumn 126, Issue 9, 2003, Pages 2034-2042

  Wanschitz, Julia ^a   Maier, Hans ^a   Lassmann, Hans ^b   Budka, Herbert ^b   Berger, Thomas ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b University of Innsbruck ^*

Author keywords

C9neo antigen; CD59; Cytotoxic T cell response; Granzyme B; Guillain Barr syndrome

Indexed keywords

ANTIGEN; CD3 ANTIGEN; CD59 ANTIGEN; CD8 ANTIGEN; CELL MARKER; COMPLEMENT COMPONENT C9; GRANZYME B; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; AUTOPSY; BIOACCUMULATION; CELL DENSITY; CELL INFILTRATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT DEPOSITION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXIC T LYMPHOCYTE; DEMYELINATION; DISEASE COURSE; DISEASE DURATION; FEMALE; GUILLAIN BARRE SYNDROME; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE COUNT; MALE; MYELIN SHEATH; PATHOPHYSIOLOGY; PERIPHERAL NERVE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCHWANN CELL; SPINAL GANGLION; SPINAL ROOT; SYMPTOM; T LYMPHOCYTE SUBPOPULATION; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD59; COMPLEMENT ACTIVATION; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GANGLIA, SPINAL; GRANZYMES; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; SERINE ENDOPEPTIDASES; SPINAL NERVE ROOTS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC; UP-REGULATION;

EID: 0042823462     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/awg207     Document Type: Article

References (63)

1. Antel JP, Arnason BG, Medof ME. Suppressor cell function in multiple sclerosis: correlation with clinical disease activity. Ann Neurol 1979; 5: 338-42.
2. Archelos JJ, Roggenbuck K, Schneider-Schaulies J, Linington C, Toyka KV, Hartung HP. Production and characterization of monoclonal antibodies to the extracellular domain of PO. J Neurosci Res 1993; 35: 46-53.
3. Armati PJ, Pollard JD, Gatenby P. Rat and human Schwann cells in vitro can synthesize and express MHC molecules. Muscle Nerve 1990; 13: 106-16.
4. Asbury AK, Arnason BG, Adams RD. The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis. Medicine (Baltimore) 1969; 48: 173-215.
5. Asbury AK, Arnason BG, Karp HR, McFarlin DE. Criteria for diagnosis of Guillain-Barre syndrome. Ann Neurol 1978; 3: 565-6.
6. Astrom KE, Webster HD, Arnason BG. The initial lesion in experimental allergic neuritis. A phase and electron microscopic study. J Exp Med 1968; 128: 469-95.
7. Behrens L, Bender A, Johnson MA, Hohlfeld R. Cytotoxic mechanisms in inflammatory myopathies. Co-expression of Fas and protective Bcl-2 in muscle fibres and inflammatory cells. Brain 1997; 120: 929-38.
8. Bien CG, Bauer J, Deckwerth TL, Wiendl H, Deckert M, Wiestler OD, et al. Destruction of neurons by cytotoxic T cells: a new pathogenic mechanism in Rasmussen's encephalitis. Ann Neurol 2002; 51: 311-8.
9. Bosboom WM, Van den Berg LH, De Boer L, Van Son MJ, Veldman H, Franssen H, et al. The diagnostic value of sural nerve T cells in chronic inflammatory demyelinating polyneuropathy. Neurology 1999; 53: 837-45.
10. Brück W, Schmied M, Suchanek G, Brück Y, Breitschopf H, Poser S, et al. Oligodendrocytes in the early course of multiple sclerosis. Ann Neurol 1994; 35: 65-73.
11. Cornblath DR, Griffin DE, Welch D, Griffin JW, McArthur JC. Quantitative analysis of endoneurial T-cells in human sural nerve biopsies. J Neuroimmunol 1990; 26: 113-8.
12. Dobersen MJ, Hammer JA, Noronha AB, MacIntosh TD, Trapp BD, Brady RO, et al. Generation and characterization of mouse monoclonal antibodies to the myelin-associated glycoprotein (MAG). Neurochem Res 1985; 10: 499-513.
13. Glauser MP, Zanetti G, Baumgartner JD, Cohen J. Septic shock: pathogenesis. Lancet 1991; 338: 732-6.
14. Gold R, Toyka KV, Hartung HP. Synergistic effect of IFN-gamma and TNF-alpha on expression of immune molecules and antigen presentation by Schwann cells. Cell Immunol 1995; 165: 65-70.
15. Gutmann L. Critical illness neuropathy and myopathy. Arch Neurol 1999; 56: 527-8.
16. Hafer-Macko CE, Sheikh KA, Li CY, Ho TW, Cornblath DR, McKhann GM, et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol 1996; 39: 625-35.
17. Hahn AF, Gilbert JJ, Feasby TE. Passive transfer of demyelination by experimental allergic neuritis serum. Acta Neuropathol (Berl) 1980; 49: 169-76.
18. Harrison BM, Hansen LA, Pollard JD, McLeod JG. Demyelination induced by serum from patients with Guillain-Barre syndrome. Ann Neurol 1984; 15: 163-70.
19. Hartung HP, Toyka KV. T-cell and macrophage activation in experimental autoimmune neuritis and Guillain-Barre syndrome. Ann Neurol 1990; 27: S57-63.
20. Hartung HP, Schwenke C, Bitter-Suermann D, Toyka KV. Guillain-Barre syndrome: activated complement components C3a and C5a in CSF. Neurology 1987; 37: 1006-9.
21. Hartung HP, Hughes RA, Taylor WA, Heininger K, Reiners K, Toyka KV. T cell activation in Guillain-Barre syndrome and in MS: elevated serum levels of soluble IL-2 receptors. Neurology 1990; 40: 215-8.
22. Hartung HP, Reiners K, Schmidt B, Stoll G, Toyka KV. Serum interleukin-2 concentrations in Guillain-Barre syndrome and chronic idiopathic demyelinating polyradiculoneuropathy: comparison with other neurological diseases of presumed immunopathogenesis. Ann Neurol 1991; 30: 48-53.
23. Hartung HP, Willison HJ, Kieseier BC. Acute immunoinflammatory neuropathy: update on Guillain-Barre syndrome. [Review]. Curr Opin Neurol 2002; 15: 571-7.
24. Honavar M, Tharakan JK, Hughes RA, Leibowitz S, Winer JB. A clinicopathological study of the Guillain-Barre syndrome. Nine cases and literature review. Brain 1991; 114: 1245-69.
25. Hughes RA. Systematic reviews of treatment for inflammatory demyelinating neuropathy. [Review]. J Anat 2002; 200: 331-9.
26. Hughes RA, Kadlubowski M, Gray IA, Leibowitz S. Immune responses in experimental allergic neuritis. J Neurol Neurosurg Psychiatry 1981; 44: 565-9.
27. Kagi D, Vignaux F, Ledermann B, Burki K, Depraetere V, Nagata S, et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994; 265: 528-30.
28. Kiefer R, Kieseier BC, Stoll G, Hartung HP. The role of macrophages in immune-mediated damage to the peripheral nervous system. [Review]. Prog Neurobiol 2001; 64: 109-27.
29. Kieseier BC, Tani M, Mahad D, Oka N, Ho T, Woodroofe N, et al. Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10. Brain 2002; 125: 823-34.
30. King G, Payne S, Walker F, Murray GI. A highly sensitive detection method for immunohistochemistry using biotinylated tyramine. J Pathol 1997; 183: 237-41.
31. Korn T, Toyka K, Hartung HP, Jung S. Suppression of experimental autoimmune neuritis by leflunomide. Brain 2001; 124: 1791-802.
32. Koski CL, Sanders ME, Swoveland PT, Lawley TJ, Shin ML, Frank MM, et al. Activation of terminal components of complement in patients with Guillain-Barre syndrome and other demyelinating neuropathies. J Clin Invest 1987; 80: 1492-7.
33. Koski CL, Estep AE, Sawant-Mane S, Shin ML, Highbarger L, Hansch GM. Complement regulatory molecules on human myelin and glial cells: differential expression affects the deposition of activated complement proteins. J Neurochem 1996; 66: 303-12.
34. Lampert PW, Kies MW. Mechanism of demyelination in allergic encephalomyelitis of guinea pigs. An electron microscopic study. Exp Neurol 1967; 18: 210-23.
35. Lilje O, Armati PJ. The distribution and abundance of MHC and ICAM-1 on Schwann cells in vitro. J Neuroimmunol 1997; 77: 75-84.
36. Linington C, Izumo S, Suzuki M, Uyemura K, Meyermann R, Wekerle H. A permanent rat T cell line that mediates experimental allergic neuritis in the Lewis rat in vivo. J Immunol 1984; 133: 1946-50.
37. Linington C, Lassmann H, Ozawa K, Kosin S, Mongan L. Cell adhesion molecules of the immunoglobulin supergene family as tissue-specific autoantigens: induction of experimental allergic neuritis (EAN) by PO protein-specific T cell lines. Eur J Immunol 1992; 22: 1813-7.
38. Maier H, Schmidbauer M, Pfausler B, Schmutzhard E, Budka H. Central nervous system pathology in patients with the Guillain-Barre syndrome. Brain 1997; 120: 451-64.
39. Mancardi GL, Cadoni A, Zicca A, Schenone A, Tabaton M, De Martini I, et al. HLA-DR Schwann cell reactivity in peripheral neuropathies of different origins. Neurology 1988; 38: 848-51.
40. Neumann H, Cavalie A, Jenne DE, Wekerle H. Induction of MHC class I genes in neurons. Science 1995; 269: 549-52.
41. Osterman PO, Fagius J, Lundemo G, Pihlstedt P, Pirskanen R, Siden A, et al. Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 1984; 2: 1296-9.
42. Radzun HJ, Hansmann ML, Heidebrecht HJ, Bodewadt-Radzun S, Wacker HH, Kreipe H, et al. Detection of a monocyte/macrophage differentiation antigen in routinely processed paraffin-embedded tissues by monoclonal antibody Ki-M1P. Lab Invest 1991; 65: 306-15.
43. Rosen AD, Vastola EF. Clinical effects of cyclophosphamide in Guillain-Barre polyneuritis. J Neurol Sci 1976; 30: 179-87.
44. Saida T, Saida K, Silberberg DH, Brown MJ. Transfer of demyelination by intraneural injection of experimental allergic neuritis serum. Nature 1978; 272: 639-41.
45. Saida T, Saida K, Lisak RP, Brown MJ, Silberberg DH, Asbury AK. In vivo demyelinating activity of sera from patients with Guillain-Barre syndrome. Ann Neurol 1982; 11: 69-75.
46. Sanders ME, Koski CL, Robbins D, Shin ML, Frank MM, Joiner KA. Activated terminal complement in cerebrospinal fluid in Guillain-Barre syndrome and multiple sclerosis. J Immunol 1986; 136: 4456-9.
47. Santamaria P. Effector lymphocytes in autoimmunity. [Review]. Curr Opin Immunol 2001; 13: 663-9.
48. Sawant-Mane S, Clark MB, Koski CL. In vitro demyelination by serum antibody from patients with Guillain-Barre syndrome requires terminal complement complexes. Ann Neurol 1991; 29: 397-404.
49. Sawant-Mane S, Estep A 3rd, Koski CL. Antibody of patients with Guillain-Barre syndrome mediates complement-dependent cytolysis of rat Schwann cells: susceptibility to cytolysis reflects Schwann cell phenotype. J Neuroimmunol 1994; 49: 145-52.
50. Sawant-Mane S, Piddlesden SJ, Morgan BP, Holers VM, Koski CL. CD59 homologue regulates complement-dependent cytolysis of rat Schwann cells. J Neuroimmunol 1996; 69: 63-71.
51. Schmidt B, Toyka KV, Kiefer R, Full J, Hartung HP, Pollard J. Inflammatory infiltrates in sural nerve biopsies in Guillain-Barre syndrome and chronic inflammatory demyelinating neuropathy. Muscle Nerve 1996; 19: 474-87.
52. Srinivasan A, Roth KA, Sayers RO, Shindler KS, Wong AM, Fritz LC, et al. In situ immunodetection of activated caspase-3 in apoptotic neurons in the developing nervous system. Cell Death Differ 1998; 5: 1004-16.
53. Stoll G, Schmidt B, Jander S, Toyka KV, Hartung HP. Presence of the terminal complement complex (C5b-9) precedes myelin degradation in immune-mediated demyelination of the rat peripheral nervous system. Ann Neurol 1991; 30: 147-55.
54. Taylor WA, Hughes RA. T lymphocyte activation antigens in Guillain-Barre syndrome and chronic idiopathic demyelinating polyradiculoneuropathy. J Neuroimmunol 1989; 24: 33-9.
55. VandenBerg LH, Mollee I, Wokke JH, Logtenberg T. Increased frequencies of HPRT mutant T lymphocytes in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy: further evidence for a role of T cells in the etiopathogenesis of peripheral demyelinating diseases. J Neuroimmunol 1995; 58: 37-42.
56. VanderMeche FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group. New Engl J Med 1992; 326: 1123-9.
57. VanDoorn PA, Garssen MP. Treatment of immune neuropathies. [Review]. Curr Opin Neurol 2002; 15: 623-31.
58. VanRhijn I, Van den Berg LH, Ang CW, Admiraal J, Logtenberg T. Expansion of human gammadelta T cells after in vitro stimulation with Campylobacter jejuni. Int Immunol 2003; 15: 373-82.
59. Vass K, Lassmann H, Wekerle H, Wisniewski HM. The distribution of Ia antigen in the lesions of rat acute experimental allergic encephalomyelitis. Acta Neuropathol (Berl) 1986; 70: 149-60.
60. Vedeler C, Ulvestad E, Bjorge L, Conti G, Williams K, Mork S, et al. The expression of CD59 in normal human nervous tissue. Immunology 1994; 82: 542-7.
61. Vedeler CA, Conti G, Fujioka T, Scarpini E, Rostami A. The expression of CD59 in experimental allergic neuritis. J Neurol Sci 1999; 165: 154-9.
62. Winer J, Hughes S, Cooper J, Ben-Smith A, Savage C. gamma delta T cells infiltrating sensory nerve biopsies from patients with inflammatory neuropathy. J Neurol 2002; 249: 616-21.
63. Zochodne DW, Bolton CF, Wells GA, Gilbert JJ, Hahn AF, Brown JD, et al. Critical illness polyneuropathy. A complication of sepsis and multiple organ failure. Brain 1987; 110: 819-41.